OTCQB Venture Market: INNV) has received an exclusive license from the University of Iowa Research Foundation for thymol and carvacrol for cachexia
, and muscle growth and repair, the company said.
According to the company, IGC-504 and IGC-506 are indicated for eating disorders, including cachexia
, a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body.
Several pieces of evidence suggest a key role for ROS in the development of muscle atrophy in response to the inflammatory profile related to cancer cachexia
The report provides a snapshot of the global therapeutic landscape of Cachexia
The high incidence and mortality rates of cancer cachexia
attract much attention in recent years (Morley et al.
The agent's unique dual mode of action, which has both anti-catabolic and pro-anabolic activity, directly impacts two of the principle pathophysiological hallmarks of cachexia
and has been shown to have beneficial effects upon both cachexia
and age-related sarcopenia in vivo.
Many strong studies now demonstrate that the carnitine supplements can reduce the rate and severity of cancer cachexia
New research shows that a molecule called pateamine A can interfere with the biochemical pathways that cause cachexia
, and may point the way toward a therapy.
affects between 50% and 80% of cancer patients, according to Nagi B.
Consultant pathologist Dr David Semeraro told her inquest that cachexia
, a wasting condi-tion caused by anorexia and chronic fatigue, contributed to her death.
Most birds presented for necropsy had lesions attributed to predation or human-related trauma; however, several budgerigars had marked cachexia
(Fig la), hepatomegaly (Fig 1b) and splenomegaly (Fig 1c and d).
Before now, cachexia
, characterized by muscle wasting and dramatic weight loss, was believed to spare the heart.
The process of muscle wastage associated with advanced cancer is known as cachexia
ADPnews) - May 20, 2010 - Belgo-Dutch biotechnology firm Galapagos NV (AMS:GLPGA, EBR:GLPG) said today it started first in-human trials with GLPG0492, its candidate drug for cachexia
or loss of weight and muscle mass.
Later, 2 isolated sick chamois found in May and October had mainly clinical signs of cachexia
and alopecia, similar to those previously observed in 2001 and 2002 (1).